MRNA
Moderna, Inc.
—
63.96 $
+2.1600 (%+3.50)
Previous Close: 61.8
Day Low₺60.73
Day High₺67.74
MRNA: Moderna, Inc. Financials
MRNA Income Statement
Total revenue
Net income
Gross margin TTM
55.35%
Operating margin TTM
-158.13%
Net profit margin TTM
-145.16%
Return on investment TTM
—
| Period end | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 1,944,000,000 | 3,199,000,000 | 6,848,000,000 | 18,875,000,000 |
| Operating income | -3,074,000,000 | -3,945,000,000 | -4,239,000,000 | 9,420,000,000 |
| Net income | -2,822,000,000 | -3,561,000,000 | -4,714,000,000 | 8,362,000,000 |
All line items
| Line item | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 1,944,000,000 | 3,199,000,000 | 6,848,000,000 | 18,875,000,000 |
| Cost of revenue | 868,000,000 | 1,464,000,000 | 4,693,000,000 | 5,416,000,000 |
| Gross profit | 1,076,000,000 | 1,735,000,000 | 2,155,000,000 | 13,459,000,000 |
| Research and development expenses | 3,132,000,000 | 4,543,000,000 | 4,845,000,000 | 3,295,000,000 |
| General and administrative expenses | 0 | 1,028,000,000 | 1,345,000,000 | 1,011,000,000 |
| Selling and marketing expenses | 0 | 146,000,000 | 204,000,000 | 121,000,000 |
| Selling, general and administrative expenses | 1,018,000,000 | 1,174,000,000 | 1,549,000,000 | 1,132,000,000 |
| Other expenses | 0 | -37,000,000 | 0 | -388,000,000 |
| Operating expenses | 4,150,000,000 | 5,680,000,000 | 6,394,000,000 | 4,039,000,000 |
| Cost and expenses | 5,018,000,000 | 7,144,000,000 | 11,087,000,000 | 9,455,000,000 |
| Net interest income | 304,000,000 | 401,000,000 | 383,000,000 | 171,000,000 |
| Interest income | 314,000,000 | 425,000,000 | 421,000,000 | 200,000,000 |
| Interest expense | 10,000,000 | 24,000,000 | 38,000,000 | 29,000,000 |
| Depreciation and amortization | 215,000,000 | 189,000,000 | 621,000,000 | 348,000,000 |
| EBITDA | -2,553,000,000 | -3,394,000,000 | -3,283,000,000 | 9,952,000,000 |
| EBIT | -2,768,000,000 | -3,583,000,000 | -3,904,000,000 | 9,604,000,000 |
| Non-operating income (excl. interest) | -306,000,000 | -362,000,000 | -335,000,000 | -184,000,000 |
| Operating income | -3,074,000,000 | -3,945,000,000 | -4,239,000,000 | 9,420,000,000 |
| Total other income/expenses (net) | 306,000,000 | 338,000,000 | 297,000,000 | 155,000,000 |
| Income before tax | -2,768,000,000 | -3,607,000,000 | -3,942,000,000 | 9,575,000,000 |
| Income tax expense | 54,000,000 | -46,000,000 | 772,000,000 | 1,213,000,000 |
| Net income from continuing operations | -2,822,000,000 | -3,561,000,000 | -4,714,000,000 | 8,362,000,000 |
| Net income from discontinued operations | 0 | 0 | 0 | 0 |
| Other adjustments to net income | 0 | 0 | 0 | 0 |
| Net income | -2,822,000,000 | -3,561,000,000 | -4,714,000,000 | 8,362,000,000 |
| Net income deductions | 0 | 0 | 0 | 0 |
| Bottom line net income | -2,822,000,000 | -3,561,000,000 | -4,714,000,000 | 8,362,000,000 |
| EPS | -7 | -9 | -12 | 21 |
| Diluted EPS | -7 | -9 | -12 | 20 |
| Weighted average shares outstanding | 389,000,000 | 384,000,000 | 382,000,000 | 394,000,000 |
| Weighted average diluted shares outstanding | 389,000,000 | 384,000,000 | 382,000,000 | 416,000,000 |